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Abstract 
Intermittent energy restriction (IER) involves short periods of severe energy restriction 
interspersed with periods of adequate energy intake, and can induce weight loss. Insulin 
sensitivity is impaired by short-term, complete energy restriction, but the effects of IER are not 
well known. In randomised order, 14 lean men (age: 25 (SD 4) y; BMI: 24 (SD 2) kg·m-2; body 
fat: 17 (4) %) consumed 24 h diets providing 100% (10441 (SD 812) kJ; EB) or 25% (2622 
(SD 204) kJ; ER) of estimated energy requirements, followed by an oral glucose tolerance test 
(OGTT; 75g glucose drink) overnight fasted. Plasma/ serum glucose, insulin, non-esterified 
fatty acids (NEFA), glucagon-like peptide-1 (GLP-1), glucose-dependant insulinotropic 
peptide (GIP) and fibroblast growth factor-21 (FGF21) were assessed before and after (0 h) 
each 24 h dietary intervention, and throughout the 2 h OGTT. Homeostatic model assessment 
of insulin resistance (HOMA2-IR) assessed the fasted response and incremental (iAUC) or 
total (tAUC) area under the curve were calculated during the OGTT. At 0 h, HOMA2-IR was 
23% lower after ER compared to EB (P<0.05). During the OGTT, serum glucose iAUC 
(P<0.001) serum insulin iAUC (P<0.05) and plasma NEFA tAUC (P<0.01) were greater 
during ER, but GLP-1 (P=0.161), GIP (P=0.473) and FGF21 (P=0.497) tAUC were similar 
between trials. These results demonstrate that severe energy restriction acutely impairs 
postprandial glycaemic control in lean men, despite reducing HOMA2-IR. Chronic 
intervention studies are required to elucidate the long-term effects of IER on indices of insulin 
sensitivity, particularly in the absence of weight loss. 
 
 
 
Introduction 1 
Obesity is the result of chronic mismanagement of energy balance and is associated with 2 
several chronic diseases(1). Recent analyses project the prevalence of obesity to continue to 3 
increase(2), with part of this increase attributable to a greater number of lean individuals gaining 4 
weight throughout adulthood(3). Daily energy restriction of 20-50% of estimated energy 5 
requirements (EER) is frequently used as a method of managing energy balance(4), yet data 6 
suggests that only ~40% of individuals manage to achieve long term weight loss(5). This may 7 
be due to the requirement for daily adherence to the diet in order to achieve a sufficiently large 8 
energy deficit for weight loss(6).  9 
Intermittent energy restriction (IER), often termed ‘intermittent fasting’, has become the 10 
subject of considerable research attention as an alternative to continuous energy restriction(7). 11 
Typically, IER permits consumption of an ad-libitum or adequate energy diet (i.e. ~100% EER) 12 
punctuated by short periods (24-48 h) of severe (~25% EER) or complete energy restriction. 13 
Previous studies have demonstrated 2-16 kg weight loss after 3-20 weeks of IER, which is 14 
comparable to losses induced with daily energy restriction(8). With IER, this weight loss may 15 
be facilitated by a subjective and hormonal appetite response conducive to the maintenance of 16 
a negative energy balance(9,10,11). As such, IER may be an effective alternative weight 17 
management strategy to traditional continuous moderate energy restriction.  18 
By nature, IER requires individuals to undergo repeated cycles of acute severe energy 19 
restriction and refeeding. It has been demonstrated that a short (12-72 h) period of complete 20 
energy restriction (i.e. fasting) causes several metabolic alterations, including a reciprocal 21 
upregulation of lipolysis to provide non-esterified fatty acids (NEFA) for oxidation, and a 22 
downregulation of glycogenolysis to conserve glycogen stores(12). This concurrently occurs 23 
with a decline in postprandial/ nutrient-stimulated insulin sensitivity and elevated plasma 24 
glucose concentrations(13). Typically IER protocols utilise partial (consuming ~25% EER) 25 
rather than complete (i.e. fasting) energy restriction, which may mitigate these effects(14). It 26 
was recently shown in overweight/ obese individuals that partial energy restriction (~25% 27 
EER) produced a more favourable postprandial glycaemic response compared to complete 28 
energy restriction, but a degree of insulin resistance was still present(14). However, metabolic 29 
regulation likely differs between lean and overweight/ obese individuals(15), as does the premise 30 
of IER (i.e. weight loss vs weight maintenance). Weight management is an integral part of 31 
reducing the prevalence of cardiometabolic disease. It has been well established that IER diets 32 
induce weight loss, which may in-itself impart a beneficial effect on risk markers for chronic 33 
disease. However, identifying whether there are specific metabolic effects of IER style diets, 34 
in lean individuals, will help determine whether IER might be used effectively as a tool for 35 
weight management(16). 36 
Therefore, the aim of this study was to investigate the acute effects of 24 h severe energy 37 
restriction (~25% EER) in lean males, on indices of glycaemic control and metabolism; 38 
including fasting and postprandial measures of glucose, insulin, NEFA, glucagon-like peptide 39 
1 (GLP-1), glucose-dependant insulinotropic peptide (GIP) and fibroblast growth factor-21 40 
(FGF-21).    41 
       42 
Methods 43 
Subjects 44 
This study was conducted according to the guidelines laid down in the Declaration of Helsinki 45 
and all procedures involving human subjects/patients were approved by the Loughborough 46 
University Ethical Sub-committee for human participants (Reference number: R15-P032). 47 
Fourteen recreationally active, weight stable (>6 months), non-dieting males (age: 25 (SD 4) 48 
y; mass: 77.8 (SD 10.2) kg; height: 1.79 (SD 0.07) m; BMI: 24 (SD 2) kg·m-2; body fat: 17 49 
(4) %) provided written informed consent to participate in the study. The sample size was based 50 
on the 2-h glucose area under the curve values for males from a previous study from our 51 
laboratory(11) that used a similar study design. Using an α of 0.05 and a β of 0.2, it was 52 
determined that 12 subjects would be required detect a 10% difference in glucose area under 53 
the curve. 54 
Study design 55 
Subject’s height (Seca, Birmingham, UK), mass (Adam AFW-120K, Milton Keynes, UK), and 56 
body fat percentage(17) were determined during a preliminary visit to the laboratory. For 57 
inclusion, subjects were required to have a BMI<25 kg·m-2 and/ or a body fat percentage 58 
<25%(18). Subjects completed two experimental trials in a randomised, counterbalanced order, 59 
with trials separated by ≥7 days. Each trial consisted of a 24 h period of either energy balance 60 
(EB) or energy restriction (ER), followed by an oral glucose tolerance test (OGTT). 61 
Pre-trial standardisation 62 
Dietary intake and physical activity in the 24 h preceding the first experimental trial were 63 
recorded, and replicated prior to the second trial. Alcohol and strenuous exercise were not 64 
permitted during this period, or during the study period. 65 
Protocol 66 
For each trial, subjects attended the laboratory on two consecutive mornings (~07:30), arriving 67 
via motorised transport after a >10 h overnight fast. Subjects were not permitted to consume 68 
food and drink additional to that provided during the study period.  69 
Day 1: On arrival, subjects were seated for 30 min before a blood sample was collected by 70 
venepuncture from an antecubital forearm vein (-24 h). Before leaving the laboratory, subjects 71 
were provided with an individually standardised diet, and instructions on when to consume 72 
each item. Subjects were asked to perform minimal activity over the day. Diets were formulated 73 
to contain either 25% (ER) or 100% (EB) of EER, with EER calculated as the product of 74 
estimated resting metabolic rate(19) and a sedentary physical activity level of 1.4. Total energy 75 
was divided between four meals during EB and between two meals during ER (Table 1). Diets 76 
were kept standardised, however, individual preferences (i.e. severe dislike to a certain food) 77 
were considered and minor alterations were made to ensure adherence. Water intake was 78 
prescribed at 35 mL·kg-1 of body mass (2853 (SD 329) mL) and was evenly distributed 79 
throughout the day. On ER, in place of breakfast (08:00), subjects consumed a bolus of water 80 
equal to the water content of the breakfast provided on EB. 81 
Day 2: Subjects returned to the laboratory the following morning and a 20-gauge cannula was 82 
inserted into an antecubital forearm vein. After 30 min seated rest, a fasted blood sample was 83 
collected (0 h). Subjects then consumed 75 g glucose dissolved in 250 mL of water, with an 84 
additional 50 mL of water used to rinse the beaker to ensure all glucose was consumed. The 85 
drink was consumed as quickly as possible and typically within 15 s. Blood samples were 86 
collected 0.25, 0.5, 0.75, 1, 1.5 and 2 h after ingestion with subjects remaining seated 87 
throughout. 88 
Blood sampling and analysis 89 
Blood samples were drawn in 12 mL volumes, with 5 mL dispensed into pre-chilled tubes 90 
containing 1.6 mg·mL-1 of potassium EDTA (Sarstedt AG & Co, Nümbrecht, Germany) and 91 
stored on ice, and 5 mL dispensed into tubes containing a clotting catalyst (Sarstedt AG & Co, 92 
Nümbrecht, Germany) and stored for 15 min at room temperature until completely clotted. 93 
Tubes were then centrifuged (1750 g; 10 min; 4°C) and plasma/ serum separated. The 94 
supernatant was stored at -20°C for later analysis. Two mL of whole blood was mixed with 95 
potassium EDTA and used for determination of haemoglobin concentration (via the 96 
cyanmethaemoglobin method) and haematocrit (via microcentrifugation) to estimate changes 97 
in plasma volume, relative to -24 h(20). Serum glucose (Horiba Medical, Montpellier, France) 98 
and plasma NEFA (Randox Laboratories Ltd, Crumlin, UK) concentrations were determined 99 
by enzymatic, colorimetric methods, using a bench-top analyser (Pentra 400, Horiba ABX 100 
Diagnostics, Montpellier, France). The intra-assay CV for serum glucose and plasma NEFA 101 
were 0.5% and 1.3%, respectively. Plasma GLP-1 (Merck Millipore, Watford, UK), GIP 102 
(Merck Millipore, Watford, UK), FGF21 (R&D Systems, Abingdon, UK) and serum insulin 103 
(Immunodiagnostic Systems, Boldon, UK) were analysed by enzyme-linked immunosorbent 104 
assays. Intra-assay CV for plasma GLP-1, GIP, FGF21 and serum insulin were 7.9%, 6.1%, 105 
3.3% and 4.7%, respectively. Serum glucose, insulin and plasma NEFA concentrations were 106 
determined at all sample time points. Plasma GLP-1, GIP and FGF21 concentrations were 107 
determined at -24, 0, 0.5, 1, 1.5 and 2 h.  108 
Calculations 109 
The updated homeostatic model of insulin resistance (HOMA2-IR) was used to calculate 110 
fasting insulin resistance before and after the dietary intervention using freely available online 111 
software (http://www.dtu.ox.ac.uk/homacalculator/). Serum glucose and insulin concentrations 112 
from the OGTT were used to assess changes in whole body insulin sensitivity using the 113 
Matsuda insulin sensitivity index(22). Incremental area under the curve (iAUC) was calculated 114 
for glucose and insulin to quantify the glycaemic response during the OGTT (0-2 h)(22). Total 115 
area under the curve (tAUC) was calculated for glucose and insulin, as well as all other variable 116 
during the OGTT (0-2 h). 117 
Statistical analysis 118 
Data were analysed using IBM SPSS 23.0 (Somers, NY, USA). Correction of hormone 119 
concentrations relative to plasma volume change did not alter the results, so the unadjusted 120 
values are presented. Fasted (-24 to 0 h) and postprandial changes (0-2 h) were analysed 121 
separately. All data were checked for normality using a Shapiro-Wilk test. Data containing one 122 
factor were analysed using a t-test or Wilcoxon signed-rank test, as appropriate. Data 123 
containing two factors were analysed using a two-way repeated measures ANOVA, followed 124 
by post-hoc Holm-Bonferroni-adjusted paired t-tests or Holm-Bonferroni-adjusted Wilcoxon 125 
signed-rank tests, as appropriate. Pearson’s r was used to explore correlations between 126 
variables indicated in text. Data sets were determined to be significantly different when P<0.05. 127 
Data are presented as mean (SD) unless otherwise stated.   128 
Results 129 
Body mass change 130 
Body mass was not different between trials at -24 h (P=0.311) but was lower at 0 h during ER 131 
(P<0.05). Body mass decreased between -24 h and 0 h during both trials (P<0.0001), but to a 132 
greater extent during ER (EB: 0.43 (SD 0.31) kg; ER: 1.26 (SD 0.43) kg; P<0.0001). 133 
Fasting metabolic measures 134 
Values for fasting variables collected before (-24 h) and after (0 h) the dietary intervention are 135 
presented in Table 2. There were trial (P<0.05) and interaction (P<0.001) effects, but no time 136 
effect (P=0.099) for serum glucose concentrations. Glucose concentrations were lower at 0 h 137 
during ER compared to EB (P<0.01). Between -24 h and 0 h, serum glucose concentrations 138 
decreased during ER (P<0.0001), but did not change during EB (P=0.578). There were time 139 
(P<0.01) and interaction (P<0.05) effects, but no trial effect (P=0.079) for serum insulin 140 
concentrations. Insulin concentrations were lower at 0 h during ER compared to EB (P<0.05). 141 
Between -24 h and 0 h, serum insulin concentrations decreased during ER (P<0.01), but did 142 
not change during EB (P=0.178). There were time (P<0.01), trial (P<0.05) and interaction 143 
(P<0.05) effects for HOMA2-IR, which was lower at 0 h during ER compared to EB (P<0.05) 144 
and decreased between -24 h and 0 h during ER (P<0.01), but did not change during EB 145 
(P=0.303; Figure 1). 146 
There were time (P<0.0001), trial (P<0.05) and interaction (P<0.0001) effects for plasma 147 
NEFA concentrations. NEFA concentrations were greater at 0 h during ER compared to EB 148 
(P<0.0001). Between -24 h and 0 h, plasma NEFA concentrations increased during ER 149 
(P<0.0001), but did not change during EB (P=0.166). There were no time (P=0.545), trial 150 
(P=0.227) or interaction (P=0.628) effects for plasma GLP-1 concentrations. There was a time 151 
effect (P<0.01), but no trial (P=0.088) or interaction (P=0.096) effects for plasma GIP 152 
concentrations. GIP concentrations decreased between -24 h and 0 h during ER (P<0.05) and 153 
tended to decrease during EB (P=0.055). There was a time effect (P<0.0001), but no trial 154 
(P=0.776) or interaction (P=0.098) effects for FGF21 concentrations. Plasma FGF21 155 
concentrations decreased between -24 h and 0 h during ER (P<0.0001) and EB (P<0.01).  156 
 157 
Postprandial metabolic responses 158 
Glucose, insulin and NEFA 159 
There were time (P<0.0001), trial (P<0.01) and interaction (P<0.0001) effects for serum 160 
glucose concentrations, with lower concentrations at 0 h and greater concentrations between 161 
0.75-1 h (P<0.05; Figure 2A) during ER compared to EB. Serum glucose iAUC (EB: 96 (SD 162 
74) mmol·L-1·2 h-1; ER: (171 (SD 102) mmol·L-1·2 h-1; P<0.001; Figure 2B) and tAUC (EB: 163 
692 (SD 101) mmol·L-1·2 h-1; ER: (757 (SD 107) mmol·L-1·2 h-1; P<0.001; Figure 2B), were 164 
greater during ER than EB and there was a trend for greater peak glucose concentrations during 165 
ER (EB: 7.93 (SD 1.52) mmol·L-1; ER: 8.44 (SD 1.46) mmol·L-1; P=0.073). Glucose time-to-166 
peak was delayed during ER compared to EB. 167 
There was no trial effect (P=0.920), but there were time (P<0.0001) and interaction (P<0.001) 168 
effects for serum insulin concentrations, with greater insulin concentrations at 2 h during ER 169 
compared to EB (P<0.05; Figure 2C). Serum insulin iAUC was greater during ER than EB 170 
(EB: 23335 (SD 10964) pmol·L-1·2 h-1; ER: 26094 (SD 10807) pmol·L-1·2 h-1; P<0.05; Figure 171 
2D), but tAUC was not different between trials (EB: 31678 (SD 11598) pmol·L-1·2 h-1; ER: 172 
(32685 (SD 11987) pmol·L-1·2 h-1; P=0.487; Figure 2D). There were no differences between 173 
trials for peak serum insulin concentrations (EB: 452 (SD 168) pmol·L-1; ER: 433 (SD 163) 174 
pmol·L-1; P=0.564) but time-to-peak was delayed during ER compared to EB. 175 
There were time (P<0.0001), trial (P<0.01) and interaction (P<0.0001) effects for plasma 176 
NEFA concentrations, with greater plasma NEFA concentrations between 0-0.5 h during ER 177 
compared to EB (P<0.01; Figure 3A). Plasma NEFA tAUC was 45% greater during ER 178 
compared to EB (EB: 22.06 (SD 9.00) mmol·L-1·2 h-1; ER: 32.09 (SD 9.44) mmol·L-1·2 h-1; 179 
P<0.01; Figure 3B). 180 
Serum glucose iAUC and pre-OGTT (0 h) plasma NEFA concentrations tended to be positively 181 
correlated (r=0.472; P=0.089), but serum glucose iAUC did not correlate with NEFA tAUC 182 
(r=-0.049; P=0.868). Serum glucose tAUC did not correlate with either plasma NEFA tAUC 183 
(r=0.112; P=0.703) nor pre-OGTT plasma NEFA concentrations (r=0.326; P=0.255). 184 
Matsuda Index 185 
The Matsuda Index of insulin sensitivity was not different between trials (EB: 7.50 (SD 4.75); 186 
ER: 7.93 (SD 5.06) P=0.603). 187 
GLP-1 and GIP responses 188 
There was a time effect (P<0.05), but no trial (P=0.219) or interaction (P=0.055) effects for 189 
plasma GLP-1 concentrations. GLP-1 tAUC was not different between trials (EB: 3207 (SD 190 
1321) pmol·L-1·2 h-1; ER: 4123 (SD 3203) pmol·L-1·2 h-1; P=0.155; Figure 4B). 191 
There was a time effect (P<0.0001), but no trial (P=0.473) or interaction (P=0.150) effects for 192 
plasma GIP concentrations. GIP tAUC was not different between trials (EB: 23874 (SD 10283) 193 
pmol·L-1·2 h-1; ER: 24287 (SD 10143) pmol·L-1·2 h-1; P=0.698; Figure 4D). 194 
FGF-21 response 195 
There was a time effect (P<0.01), but no trial (P=0.513) or interaction (P=0.763) effects for 196 
plasma FGF-21 concentrations. FGF-21 tAUC was not different between trials (EB: 8000 (SD 197 
4038) pg·mL-1·2 h-1; ER: 7553 (SD 5171) pg·mL-1·2 h-1; P=0.511; Figure 5).  198 
Discussion 199 
The aim of this study was to determine the acute effects of 24 h severe energy restriction on 200 
indices of insulin sensitivity. The results demonstrate that postprandial glycaemic control is 201 
impaired, despite a reduction in HOMA2-IR after 24 h severe energy restriction. These findings 202 
may have implications for the efficacy of intermittent energy restriction diets, particularly for 203 
weight maintenance, where weight loss related improvements in insulin sensitivity might not 204 
be anticipated.     205 
Undergoing short periods of severe energy restriction (consuming ~25% of EER) is a requisite 206 
component of an IER diet, and has been shown to be an effective method of reducing daily 207 
energy intake in lean(9,11) and overweight/ obese(10,14) populations. Three to twelve weeks of 208 
IER has been demonstrated to cause significant weight and fat mass losses, comparable to that 209 
achieved with moderate daily energy restriction of similar duration(8). Importantly, several 210 
studies have reported improvements in fasting insulin sensitivity indexes after 4-6 months of 211 
IER(6,23). In the current study, HOMA2-IR decreased 23% after 24 h of severe energy restriction 212 
(ER) compared to an adequate energy intake control trial (EB). However, in response to an oral 213 
glucose challenge, serum glucose tAUC ~was 9% greater (iAUC was ~78% greater) and serum 214 
insulin iAUC was ~12% greater, during ER compared to EB. In addition, peak serum glucose 215 
concentration was 6% greater and serum glucose remained elevated for longer, during ER. This 216 
data suggests that glycaemic control was impaired after a single 24 h period of severe energy 217 
restriction in a group of young, lean men.  218 
These results could be explained by a simple alteration in substrate availability. A short period 219 
of severe energy restriction may deplete hepatic glycogen stores and reduce endogenous 220 
glucose production(24). Consequently, circulating glucose and insulin are also reduced(25). As 221 
HOMA2-IR is a product of fasting glucose and insulin concentrations, these acute metabolic 222 
changes that occur with severe energy restriction limit the validity of HOMA2-IR to assess 223 
insulin sensitivity in this context. The reduction observed in this and similar studies may reflect 224 
a reduced requirement for insulin secretion, rather than an improvement in insulin sensitivity 225 
per se. Similarly, despite increases in fed-state serum glucose and insulin concentrations during 226 
the OGTT, the composite Masuda Index of insulin sensitivity was unaffected by ER. This may 227 
be due to the incorporation of fasting glucose and insulin concentrations in the calculation of 228 
the index(26,27).  229 
When exogenous glucose availability is low, insulin concentrations are also low, stimulating 230 
lipolysis to mobilise triglycerides for oxidation(28). As evidenced in the current study, this leads 231 
to an increase in plasma NEFA concentrations, and previous studies, utilising a very similar 232 
energy restriction protocol, have also reported an increase in fat oxidation and a concomitant 233 
decrease in carbohydrate oxidation in both the fasted and postprandial state(10,11,14). A 234 
consequence of increased fat oxidation is the accumulation of acetyl-CoA, NADH and citrate, 235 
which can inhibit both upstream (via inhibition of phosphofructo-kinase) and downstream (via 236 
inhibition of GLUT4 translocation and pyruvate dehydrogenase) glycolysis(29). Elevated 237 
plasma NEFA concentrations have also been postulated to cause mitochondrial overload, 238 
resulting in incomplete fatty acid oxidation and the accumulation of toxic fatty acid 239 
intermediates, such as diacylglycerol and ceramide which may impair insulin signalling(30). 240 
However, impairments in skeletal muscle insulin signalling are not a prerequisite for reduced 241 
muscle glucose uptake, and rapid impairments in the ability to process exogenous (ingested or 242 
infused) glucose might be explained by reduced glycolytic flux/ oxidative disposal. For 243 
example, Lundsgaard et al.(31) reported that 3 days of overfeeding with carbohydrate, increased 244 
leg glucose uptake during a hyperinsulinemic-euglycemic clamp, whereas 3 days of high-fat 245 
overfeeding reduced glucose uptake despite normal insulin signalling. It was suggested that 246 
greater TCA influx from beta-oxidation-derived acetyl-CoA might explain the reduced glucose 247 
uptake in the absence of changes in insulin signalling. Evidence for this was provided by the 248 
observations that  high fat diet adherence led to a significant decrease in total PDH-E1α protein 249 
content (the enzyme responsible for catalysing the conversion of pyruvate to acetyl-CoA) as 250 
well as increased Ser300 phosphorylation (i.e., reduced PDH activity) and increased glucose-6-251 
phosphate accumulation(31). Hence, in the context of the current study, elevated NEFA (a 252 
surrogate for increased lipolysis and greater dependency upon fat oxidation) likely decreased 253 
glucose uptake/ oxidation by a similar mechanism.    254 
Several findings from the current study are analogous to a similar study which investigated the 255 
effects of 24 h severe energy restriction in overweight and obese subjects(14). Postprandial 256 
insulin iAUC was greater after severe energy restriction in the current study, a finding that 257 
differs from Antoni et al.(14), but average time-to-peak insulin concentration appeared to be 258 
delayed after severe energy restriction in both studies, suggesting an impaired early-phase 259 
insulin response. Early-phase insulin has been shown to more potently lower blood glucose 260 
concentrations compared to late-phase insulin(32). This might therefore explain the greater peak 261 
glucose concentrations observed after severe energy restriction in the current study and Antoni 262 
et al.(14). Together, these findings demonstrate that 24 h severe energy restriction impairs 263 
glycaemic control in both lean (current study) and overweight/ obese(14) subjects, with both 264 
studies indicating that early-phase insulin response may be a casual factor. 265 
This response is similar to the ‘second meal effect’, which describes an improved glycaemic 266 
response to a meal after consumption of glucose at a prior eating occasion(33). It is thought that 267 
the impairment in early-phase insulin response observed with the ‘second meal effect’ is 268 
mediated by prolonged exposure of the pancreatic islet cells to elevated NEFA concentrations, 269 
shown in vitro to inhibit insulin secretion(34). Whilst this cannot be determined in the present 270 
study, plasma NEFA concentrations were greater prior to the OGTT during ER, indicating that 271 
plasma NEFA concentrations were also likely greater during ER in previous 24 h. This would 272 
suggest pancreatic islet cells were exposed to prolonged elevated plasma NEFA concentrations 273 
during ER, possibly leading to impaired early-phase response to the glucose load. This is 274 
partially supported by a tendency for a positive correlation between pre-OGTT plasma NEFA 275 
concentrations and serum glucose iAUC, and an apparent delay in time-to-peak insulin 276 
concentration during ER.   277 
It is interesting to note that, despite several studies demonstrating an impairment in glycaemic 278 
control after severe energy restriction at rest, a recent study found that restricting carbohydrate 279 
intake after evening exercise improved post-prandial glycaemic control the following morning, 280 
compared to when carbohydrate was consumed in a quantity equal to that expended during 281 
exercise (90 min running at 70% VO2max)(35). This is quite different to the present and 282 
previous studies, which have restricted total energy intake during periods of minimal physical 283 
activity. Under such conditions, energy restriction will have little influence on muscle glycogen 284 
content (the primary site of insulin-mediated glucose disposal). It also demonstrates that the 285 
so-called [acute] insulin sensitising effect of exercise centres on creating a ‘sink’ for glucose 286 
disposal. Further investigation is certainly necessary in this field as both exercise and dietary 287 
restriction are important components of successful weight management strategies(36). 288 
There are several biological mechanisms involved in the regulation of energy homeostasis. 289 
GLP-1 and GIP are incretin hormones secreted rapidly from the intestine in response to food 290 
ingestion(37). These hormones respond prior to nutrient absorption, and stimulate the secretion 291 
of insulin from the pancreas to assist with the disposal of glucose from the blood(37). In the 292 
current study, whilst GIP was elevated after consumption of the glucose solution in both trials, 293 
severe energy restriction did not appear to differentially affect circulating incretin hormone 294 
concentrations, compared to an energy balance control trial. Plasma GLP-1 and GIP 295 
concentrations were similarly unaffected by short-term (seven days) high-fat (65% of energy) 296 
overfeeding (~150% EER), despite subjects in this study also exhibiting impaired postprandial 297 
glycaemic control(38). It should be noted that total GLP-1 and GIP were assessed in the current 298 
study and Parry et al.(38), as oppose to the biologically active (GLP-17-36; GIP1-42) form. 299 
However, assessing total GLP-1/ GIP is considered appropriate for estimating the secretion of 300 
active GLP-1/ GIP from the intestine(39). None-the-less, these studies suggest incretin 301 
hormones are resistant to short-term fluctuation in energy balance and are unlikely to be 302 
involved in acute impairments in glycaemic regulation in these settings.  303 
FGF21 is a novel hepatokine secreted in response to fasting and feeding cycles(39), which 304 
positively correlates with obesity, type-2 diabetes, insulin resistance and impaired glucose 305 
tolerance in humans(40,41). FGF21 is thought to be involved in coordinating the adaptive 306 
response to energy restriction via several mechanisms, such as encouraging ketosis, lowering 307 
blood glucose, increasing insulin sensitivity, and potentially modulating appetite regulation via 308 
the Agouti-related peptide and neuropeptide Y pathways(42). It should be noted that most 309 
studies that have found a physiological effect of energy restriction on FGF21 have been rodent 310 
studies, with FGF21 concentrations shown to increase rapidly (within 6 h) after the onset of 311 
fasting(43). In contrast, human studies have observed no change in fasting or postprandial 312 
(OGTT) plasma FGF21 concentration after 16 h fasting(44), and one study found that it may 313 
take 7-10 days of fasting to elicit an increase in FGF21 in humans(45). In line with this, the 314 
current study found no effect of 24 h severe energy restriction on fasting or postprandial plasma 315 
FGF21 concentrations. This strengthens evidence that nutritional regulation of FGF21 differs 316 
between rodents and humans(44).  317 
Whilst the exact mechanism of metabolic dysregulation may be elusive at present, results from 318 
several acute studies now indicate that a short period of severe energy restriction leads to a 319 
subsequent period of impaired glycaemic control(9-11,14). The clinical significance of these 320 
findings cannot be extrapolated from these acute studies, but oscillating postprandial glucose 321 
concentrations are thought to directly contribute to the development of cardiovascular 322 
disease(46), and a delay in the postprandial glucose curve is associated with impairments in β-323 
cell function and insulin secretion(47). Whether these acute impairments in glycaemic control 324 
are improved or exacerbated with multiple restriction and refeeding cycles is not fully known. 325 
The only available data on long-term IER is from a rodent study, which found that 32 weeks 326 
of intermittent fasting and refeeding promoted redox imbalance, oxidative modification of 327 
insulin receptors and a progressive decline in glucose tolerance, despite an initial improvement 328 
in glucose tolerance after 4 weeks(48). These data suggest that irregular feeding patterns leading 329 
to increased exposure to elevated blood glucose concentrations may have the potential to impair 330 
insulin-mediated glucose uptake.  331 
Future studies should investigate the long-term effects of an IER diet on glycaemic control in 332 
humans, including the dynamic assessment of glucose uptake and oxidation, as alterations may 333 
not be evident in the fasted state(16). A recent study compared the effects of achieving ~5% 334 
weight loss via IER (consuming ~25% EER on two consecutive days, with a self-selected 335 
adequate-energy diet on the remaining five days of the week) or CER (consuming 2510 kJ 336 
below EER for seven days of the week), in a group of overweight/ obese subjects. Fasted 337 
variables showed no difference between the dieting methods, however postprandial insulin 338 
sensitivity markers revealed a significant reduction in C-peptide after IER whilst C-peptide 339 
was unaltered after CER(50). C-peptide is secreted in equimolar amounts to insulin, but 340 
undergoes minimal extraction at the liver so may be a more robust measure of insulin secretion 341 
than circulating insulin concentrations(51). This change in C-peptide did not appear to influence 342 
postprandial glycaemic control, and comparable reductions in postprandial insulin 343 
concentrations were observed with both diets. However, this finding does indicate differences 344 
in mechanisms of action between IER and CER, potentially suggesting IER may improve 345 
insulin sensitivity to a greater extent than CER after semi-chronic (~2 months) adherence. This 346 
warrants further investigation, as does identifying the effects of long-term IER in the absence 347 
of weight loss. This will be crucial for determining whether IER can be used as an effective 348 
weight maintenance strategy, with this being an important target for reducing rates of obesity 349 
related comorbidities in the future(3).   350 
In conclusion, this study has demonstrated that 24 h severe energy restriction leads to impaired 351 
postprandial glycaemic control, which cannot be detected in the fasted state. These findings 352 
have implications for IER diets and demonstrate the need for future studies to identify the 353 
accumulative impact of repeated episodes of short-term severe energy restriction on glycaemic 354 
control in lean individuals.   355 
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  499 
Tables 500 
Table 1. Energy and macronutrient intake at each meal (meal time in brackets) during day 1  501 
 Energy balance (EB) Energy restriction (ER) 
Breakfast (08:00) 
 Mean SD Mean SD 
Protein (g) 14 1 0 0 
Carbohydrate (g) 89 7 0 0 
Fat (g) 9 1 0 0 
Fibre (g) 1 0 0 0 
Energy (kJ) 2097 163 0 0 
Foods Cereal, semi-skimmed milk, 
orange juice 
Water 
Lunch (12:00) 
 Mean SD Mean SD 
Protein (g) 46 3 36 3 
Carbohydrate (g) 72 6 7 2 
Fat (g) 29 3 3 1 
Fibre (g) 5 0 2 0 
Energy (kJ) 3124 243 874 68 
Foods White bread, mayonnaise, 
chicken, lettuce, tomato, red 
pepper, balsamic vinegar, 
chocolate-chip cookies 
Chicken, lettuce, tomato, red 
pepper, balsamic vinegar 
Snack (16:00) 
 Mean SD Mean SD 
Protein (g) 5 0 0 0 
Carbohydrate (g) 31 2 0 0 
Fat (g) 11 1 0 0 
Fibre (g) 1 0 0 0 
Energy (kJ) 1040 80 0 0 
Foods Yoghurt, cereal bar NA 
Dinner (19:30) 
 Mean SD Mean SD 
Protein (g) 45 3 33 2 
Carbohydrate (g) 138 11 55 4 
Fat (g) 28 2 7 1 
Fibre (g) 5 0 3 0 
Energy (kJ) 4180 326 1748 136 
Foods Pasta, Bolognese sauce, chicken, 
olive oil, chocolate-chip cookies 
Pasta, Bolognese sauce, chicken, 
olive oil 
Total 
 Mean SD Mean SD 
Protein (g) 110 7 69 4 
Carbohydrate (g) 329 25 62 6 
Fat (g) 78 8 10 1 
Fibre (g) 12 1 4 0 
Energy (kJ) 10441 812 2622 204 
 502 
 503 
  504 
Table 2. Blood variables after 24 h of an energy balance (100% EER; EB) or severely energy 505 
restricted diet (25% EER; ER).   506 
 EB ER Interaction 
effect  -24 h 0 h -24 h 0 h 
 Mean SD Mean SD Mean SD Mean SD  
Glucose 
(mmol·L-1) 
5.4 0.4 5.5 0.6 5.3 0.3 5.0 † * 0.4 0.002 
Insulin 
(pmol·L-1) 
76 32 70 30 76 34 55 † * 20 0.029 
HOMA2-
IR 
2.68 1.23 2.49  1.36 2.63  1.26 1.79 † * 0.77 0.022 
NEFA 
(mmol·L-1) 
0.37 0.12 0.43  0.19 0.32  0.16 0.69 † * 0.22 0.001 
GLP-1 
(pmol·L-1) 
27  14 27  11 30  20 32  14 0.628 
GIP 
(pmol·L-1) 
59  26 50  31 77  47 48 * 22 0.096 
FGF21 
(pg·mL-1) 
102  63 71 * 39 118  85 65 * 47 0.098 
HOMA2-IR, homeostatic model of insulin resistance; NEFA, non-esterified fatty acids; GLP-507 
1, glucagon-like peptide-1; GIP, glucose-dependant insulinotropic peptide. † indicates values 508 
were significantly different to EB (P<0.05); * indicates values are significantly different to -24 509 
h during the corresponding trial (P<0.05).  510 
  511 
Figure Legends 512 
Figure 1. Bar chart (A) represents mean homeostatic model of insulin resistance (HOMA2-IR) 513 
values calculated from overnight fasting serum glucose and insulin concentrations before (-24 514 
h) and after (0 h) consumption of a 24 h energy balanced (EB; ■) or energy restricted (ER; □) 515 
diet. Data are mean with vertical error bars representing standard deviation.  Line graph (B) 516 
shows individual HOMA2-IR values at 0 h during EB (■) and ER (○). † indicates values were 517 
significantly different to EB at 0 h; # indicates values were significantly different to -24 h 518 
during ER (P<0.05).   519 
Figure 2. Serum glucose (A) and insulin (C) concentrations during a 2 h oral glucose tolerance 520 
test (OGTT) conducted after consumption of a 24 h energy balanced (EB; ■) or energy 521 
restricted (ER; ○) diet. Bar charts represent serum glucose (B) and insulin (D) incremental 522 
(iAUC) and total (tAUC) area under the curve during the OGTT (0-2 h) for EB (■) and ER (□). 523 
Data are means with vertical error representing standard deviation. † indicates iAUC values 524 
were significantly different to EB; # idicates tAUC values were significantly different to EB 525 
(P<0.05).  526 
Figure 3. Plasma non-esterified fatty acid (NEFA) (A) concentrations during a 2 h oral glucose 527 
tolerance test (OGTT) conducted after consumption of a 24 h energy balanced (EB; ■) or 528 
energy restricted (ER; ○) diet. Bar chart represents plasma NEFA (B) total area under the curve 529 
during the OGTT (0-2 h) for EB (■) and ER (□). Data are means with vertical error representing 530 
standard deviation. † indicates values were significantly different to EB (P<0.05).   531 
Figure 4. Plasma glucagon-like peptide-1 (GLP-1) (A) and glucose-dependant insulinotropic 532 
peptide (GIP) (C) concentrations during a 2 h oral glucose tolerance test (OGTT) conducted 533 
after consumption of a 24 h energy balanced (EB; ■) or energy restricted (ER; ○) diet. Bar 534 
charts represent plasma GLP-1 (B) and GIP (D) total area under the curve during the OGTT 535 
(0-2 h) for EB (■) and ER (□). Data are means with vertical error representing standard 536 
deviation. 537 
Figure 5. Plasma fibroblast growth factor-21 (FGF21) (A) concentrations during a 2 h oral 538 
glucose tolerance test (OGTT) conducted after consumption of a 24 h energy balanced (EB; ■) 539 
or energy restricted (ER; ○) diet. Bar chart represent plasma FGF21 (B) total area under the 540 
curve during the OGTT (0-2 h) for EB (■) and ER (□). Data are means with vertical error 541 
representing standard deviation. 542 
